Chimeric antigen receptor (CAR) therapy in infectious diseases: emerging applications with a focus on invasive fungal infections.

Authors

Carme Bracke, Ignacio Grafia, Pedro Puerta-Alcalde

Published in

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. Aug 17, 2026. Epub Aug 17, 2026.

Abstract

Infections remain a major cause of morbidity and mortality among immunocompromised patients, particularly in the context of invasive fungal infections (IFIs), where outcomes are strongly dependent on host immune status. Despite advances in antifungal therapy, mortality remains high, highlighting the need for novel immunotherapeutic strategies.
This review aims to summarize current evidence on chimeric antigen receptor (CAR)-based therapies for infectious diseases, with a particular focus on IFIs, and to discuss their potential role, limitations, and future perspectives.
A narrative review of the literature was conducted using PubMed, focusing on preclinical and clinical studies evaluating CAR-based approaches in fungal, viral, and selected bacterial infections. Relevant references were identified from database searches and cross-referencing of key articles.
CAR-engineered immune cells, particularly CAR T cells, represent a promising strategy to restore pathogen-specific immunity in immunocompromised hosts. In IFIs, targeting conserved fungal cell wall components such as β-glucans and mannans has shown encouraging preclinical results, with different CAR constructs demonstrating enhanced antifungal activity and immune activation, particularly against Aspergillus and Candida species. Alternative platforms, including CAR-NK cells and CAR macrophages, may offer advantages such as reduced toxicity and off-the-shelf availability, and have shown preliminary clinical feasibility in a patient with IFI. While CAR-based approaches have also demonstrated activity against viral and selected bacterial pathogens, their clinical application remains largely exploratory. Several challenges limit translation into clinical practice, including complex manufacturing, delayed availability, safety concerns, antigen heterogeneity, and limited clinical evidence.
CAR-based immunotherapy represents a novel and potentially transformative approach for the management of severe infections in immunocompromised patients, particularly those with refractory or multidrug-resistant disease. Advances in manufacturing, target selection, and combination strategies will be essential to overcome current limitations. Further clinical studies are needed to define their safety, efficacy, and positioning within existing therapeutic frameworks.

PMID:
42607832
Bibliographic data and abstract were imported from PubMed on 18 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.